Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.030
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap
February 01, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Submission of IND for Planned Phase 1b Hypertension Trial
January 30, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria's Submits Investigational New Drug Application
January 30, 2024
Via
ACCESSWIRE
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
Via
ACCESSWIRE
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
January 04, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs
January 29, 2024
Via
Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Shares Company Update in Annual Shareholder Letter
January 24, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Releases Annual Letter from the CEO
January 24, 2024
Via
ACCESSWIRE
LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024
January 22, 2024
Lexaria Bioscience just reported results for the first quarter of 2024.
Via
InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study
January 17, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study
January 17, 2024
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
January 11, 2024
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
Via
Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Via
FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 09, 2024
From
Lexaria Bioscience Corp.
Via
GlobeNewswire
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of Rybelsus(R)-Branded GLP-1 Drug Semaglutide
January 04, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology
December 27, 2023
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology
December 27, 2023
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push
December 26, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push
December 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) To File its IND Application with the FDA for its planned U.S. Phase 1b Hypertension Clinical Trial
December 21, 2023
Via
Investor Brand Network
Exposures
Product Safety
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting New and More Lucrative Global Markets
December 15, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology
December 13, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.